Mechanisms of cancer cell rescue against pancreatic cancer therapeutics: Intrinsic and acquired resistance
Authors:
Open Access
- 23 April 2025
- journal article
- Published by Probiologists Limited in Journal of Cancer Biology
- Vol. 6 (1) , 10-22
Abstract
Pancreatic Cancer (PC) with dismal prognosis poses a significant challenge to healthcare systems worldwide. PC is the fourth leading cause of cancer-related mortality globally and is projected to surpass lung cancer as the second foremost cause by 2030. The poor prognosis associated with PC is primarily due to the low rate of early detection, rapid progression, and limited treatment options. Chemotherapy remains a cornerstone of treatment for PC in all stages of disease. However, optimistic effects for the treatment options have been hampered by a high rate of non-responders. Resistance to treatments may arise due to various molecular mechanisms, namely intrinsic and acquired chemoresistance due to changes in genetic and epigenetic framework, drug metabolism and efflux, and tumor microenvironment. This review majorly focuses on mechanisms of cell cycle dysregulation and hypoxia induced acidosis leading to development of therapeutic resistance and poor clinical outcome. Comprehensive understanding of these resistance mechanisms could play a central role in the development of effective therapeutic strategies for improved prognosis.Keywords
This publication has 79 references indexed in Scilit:
- Liposomal Irinotecan: A Review as First-Line Therapy in Metastatic Pancreatic AdenocarcinomaDrugs, 2025
- Advances in Novel Targeted Therapies for Pancreatic AdenocarcinomaJournal of Gastrointestinal Cancer, 2025
- Overcoming therapy resistance in pancreatic cancer: New insights and future directionsBiochemical Pharmacology, 2024
- CDK regulators—Cell cycle progression or apoptosis—Scenarios in normal cells and cancerous cells2023
- Metabolic reprogramming of immune cells in pancreatic cancer progressionBiomedicine & Pharmacotherapy, 2022
- Efficacy and safety of PARP inhibitors in patients with BRCA-mutated advanced breast cancer: A meta-analysis and systematic reviewThe Breast, 2021
- Advances in the epidemiology of pancreatic cancer: Trends, risk factors, screening, and prognosisCancer Letters, 2021
- SF3B1 mutation in pancreatic cancer contributes to aerobic glycolysis and tumor growth through a PP2A–c‐Myc axisMolecular Oncology, 2021
- Pancreatic cancer treatment: better, but a long way to goSurgery Today, 2020
- Cyclin A in cell cycle control and cancerCellular and Molecular Life Sciences, 2002